Revealis enters cancer vaccine race with TEIPP strategy
Dutch startup Revealis Biotherapeutics has launched to develop cancer vaccines that target tumor cells capable of evading T-cell recognition. The company aims to improve immunotherapy outcomes by focusing on TEIPP peptides.
Why it matters
This approach addresses a major hurdle in cancer treatment—tumor resistance to immunotherapy—potentially offering new hope for patients who do not respond to current checkpoint inhibitors.
Dutch startup Revealis Biotherapeutics has launched to develop a new generation of cancer vaccines targeting tumor cells that have become difficult for T cells to recognize, building on an academic program that has already reached patients.
Why it matters: The company is going after a mechanism of resistance to cancer immunotherapy rather than the conventional tumor antigens targeted by many therapeutic vaccines. The approach could potentially complement checkpoint inhibitors and other T-cell therapies by attacking cancer cells that have escaped their initial immune pressure.
How it works: Tumors can evade T cells by disrupting their antigen-processing machinery, including by reducing the activity of TAP proteins that help display tumor antigens on the cell surface.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in